國家衛生研究院 NHRI:Item 3990099045/6840
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 958134      線上人數 : 800
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6840


    題名: Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma
    作者: Yen, Y;So, S;Rose, M;Saif, MW;Chu, E;Chen, L;Liu, S;Foo, A;Tilton, R;Cheng, Y
    貢獻者: National Institute of Cancer Research
    摘要: PHY906, a Chinese medicine formula, has been used for 1,700 years for the treatment of diarrhea, vomiting, nausea, stomach cramps, and fever. PHY906 was found to potentiate the antitumor efficacy of capecitabine in hepatocellular carcinoma (HCC) xenografts. A Phase I/II, multicenter, open-label, dose-escalation, safety and efficacy study of capecitabine / PHY906 was initiated in patients with advanced HCC. Patients were required to have measurable, recurrent, metastatic, or unresectable HCC, Karnofsky status of 70% or above, and adequate organ and hematologic parameters. Study objectives were: Phase I - to determine the safety and tolerability of the two-drug combination; Phase II - to measure antitumor response and to assess patients' quality of life (QoL). Patients were considered evaluable after two cycles of treatment. The initial dose regimen (capecitabine 1,000 mg/m2 BID; PHY906 1,000 mg BID) was found to have unfavorable toxicities. Thus, capecitabine was reduced to 750 mg/m2 BID and PHY906 to 600 mg BID. Subsequently, a new cohort of 750 mg/m2 BID capecitabine plus 800 mg BID PHY906 was added. Both latter regimens were well tolerated (N=4 for PHY906 600 mg BID, N=26 for PHY906 800 mg BID). The capecitabine 750 mg/m2 BID and PHY906 800 mg BID regimen was used for the Phase II study. Thirty-four patients participated in the Phase II study; 31 at US sites and 3 at Taiwan sites. Among the 27 evaluable patients at US sites, four (14.8%) achieved minor response (MR), 14(51.9%) had stable disease (SD), and 9(33.3%) exhibited progressive disease after two cycles of treatment. Median survival time was higher for the 20 Child-Pugh A patients (10.9 months vs. 9.2 months overall). Asian patients (N=12) had a higher overall 12-month survival rate (68%) than non-Asians (26%, N=15)[p=0.02]. Patients' QoL did not appear to deteriorate significantly during treatment. Based on the results obtained with Child-Pugh A patients, additional Phase II studies in such patients in which the effectiveness of the capecitabine / PHY906 combination is compared to that of sorefinib (recently approved for the treatment of HCC) appear warranted.
    日期: 2008-05
    關聯: Journal of Clinical Oncology. 2008 May;26(15 Suppl):Abstract number 4610.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4610?sid=23f0f966-279d-4a8c-9ecd-e100239e8286
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000208457401369
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000208457401369.pdf96KbAdobe PDF223檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋